Mon, Mar 2, 2015, 7:24 AM EST - U.S. Markets open in 2 hrs 6 mins


% | $
Quotes you view appear here for quick access.

GTX Inc. Message Board

  • ahpinvestmentz ahpinvestmentz Jul 11, 2013 3:22 PM Flag

    Who to trust... Adam Finklestein (journalist w/ ) or David M. Nierengarten (analyst)

    Adam Finklestein has a bachelor's in political science or David Nierengarten who has a PHD in BioChemistry from Berkeley .... call me crazy but after Mr. Nierengarten found Mr. Frinklestein's article as unfounded and countered all of his points.... GTXI is a winner.... the only thing Mr. Finklestein did was present a great buying opportunity.
    Wedbush today maintained an Outperform rating on GTX Inc. (NASDAQ: GTXI) with a price target of $9.00. GTX Inc shares declined sharply yesterday in response to a negative article in The Street. Analyst David M. Nierengarten called criticisms of phase IIB Enobosarm trial "unfounded" and he thinks investors should buy weakness.
    "While we usually do not respond to a journalist repeating a short-seller's thesis on a covered stock, the 25% drop intraday compels us to respond," said Nierengarten.
    "First, regarding data quality and baseline characteristics: the article states that baseline characteristics favored the enobosarm arms (the treated patients began the trial with less severe disease). The actual Lancet paper on the Phase IIB trial shows that if anything, the evaluated patients had lost more lean body mass in the 1 mg group and were comparable between placebo and the 3 mg arm (10.2% of lean body mass compared to 7.9% in placebo and comparable to 7.5% loss in the 3 mg arm), and median stair climb power was worse at baseline in both evaluable enobosarm groups compared to evaluable placebo subjects (placebo group output of #$%$ compared to 66 watts in the enobosarm groups, from the text)," said Nierengarten.
    "Second, the opinion piece emphasizes mean and median measures of the Phase II study, claiming the populations overlap and therefore there is no treatment effect, and this will be demonstrated in the Phase III. This comment ignores the design of the Phase III studies, which use a responder analysis," he added.
    "According to the peer-reviewed Lancet publication, the Phase IIB trial reported a 61% response rate for phy

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.80+0.01(+1.27%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.